Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection

被引:111
作者
Staprans, S
Marlowe, N
Glidden, D
Novakovic-Agopian, T
Grant, RM
Heyes, M
Aweeka, F
Deeks, S
Price, RW
机构
[1] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[2] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Dept Clin Pharmacol, San Francisco, CA 94143 USA
[5] NIMH, Gladstone Inst Virol & Immunol, Bethesda, MD 20892 USA
[6] NIMH, Lab Neurotoxicol, Bethesda, MD 20892 USA
关键词
AIDS; AIDS dementia complex; antiviral; cerebrospinal fluid; HIV; meningitis; quinolinic acid; RNA; treatment; viral load;
D O I
10.1097/00002030-199906180-00008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To compare the kinetics and magnitude of HIV-1 RNA responses to antiretroviral therapy (ART) in the cerebrospinal fluid (CSF) and plasma. Design: Repeated lumbar punctures (LPs) were performed after the initiation or change in ART in 15 HIV-1-infected subjects, with the focus on two phases of response: an acute phase within the first 11 days, for which crude estimates of viral RNA half-lives and decay rates were derived and CSF : plasma relative decay ratios quantitatively analysed; and a longer-term phase beyond 4 weeks that was descriptively assessed. Results: In 13 subjects studied during the acute phase, the crude HIV-1 RNA half-life was longer (median 2.0 compared with 1.9 days), the decay rate slower (median 0.13 compared with 0.16 log(10) copies/day) and, most notably, the variability greater (intraquartile range of half-life 1.8-4.3 compared with 1.7-2.1 days) in the CSF than in the plasma. A slower decay in the CSF correlated with lower initial blood CD4 T lymphocyte counts (P = 0.001). Seven of 11 subjects studied at 4 weeks or later, including some with slower acute-phase CSF responses, showed greater or more durable viral suppression in the CSF. Conclusion: Divergent acute-phase viral kinetics in the CSF and plasma, and proportionally greater long-term decrements in CSF HIV-1 RNA in slow early-responders or poor overall plasma responders indicate variable compartmentalization of CSF infection, consistent with a model of two prototypes of CSF infection: short-lived, transitory infection that predominates in early HIV-1 infection and longer-lived, more autonomous CSF infection predominating in late HIV-1 infection. Additional studies will be needed to define more precisely the acute and longer-term CSF kinetics in different clinical settings and to assess this model. (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:1051 / 1061
页数:11
相关论文
共 44 条
[1]   Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex [J].
Aweeka, F ;
Jayewardene, A ;
Staprans, S ;
Bellibas, SE ;
Kearney, B ;
Lizak, P ;
Novakovic-Agopian, T ;
Price, RW .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1999, 20 (01) :39-43
[2]   Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage [J].
Brew, BJ ;
Pemberton, L ;
Cunningham, P ;
Law, MG .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (04) :963-966
[3]  
Brinkman K, 1998, AIDS, V12, P537
[4]   Cerebrospinal fluid HIV-1 RNA levels: correlation with HIV encephalitis [J].
Cinque, P ;
Vago, L ;
Ceresa, D ;
Mainini, F ;
Terreni, MR ;
Vagani, A ;
Torri, W ;
Bossolasco, S ;
Lazzarin, A .
AIDS, 1998, 12 (04) :389-394
[5]  
DEEKS S, 1998, IN PRESS ANTIMICROB
[6]   Neurological disorders during HIV-1 infection correlate with viral load in cerebrospinal fluid but not with virus phenotype [J].
Di Stefano, M ;
Monno, L ;
Fiore, JR ;
Buccoliero, G ;
Appice, A ;
Perulli, LM ;
Pastore, G ;
Angarano, G .
AIDS, 1998, 12 (07) :737-743
[7]  
DICKSON D, 1995, J NEUROAIDS, V1, P57
[8]  
DiStefano M, 1997, AIDS, V11, P698
[9]   Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome [J].
Ellis, RJ ;
Hsia, K ;
Spector, SA ;
Nelson, JA ;
Heaton, RK ;
Wallace, MR ;
Abramson, I ;
Atkinson, JH ;
Grant, I ;
McCutchan, JA ;
Marcotte, T ;
Chandler, JL ;
Jernigan, T ;
Masliah, E ;
Abramson, I ;
Dupont, R .
ANNALS OF NEUROLOGY, 1997, 42 (05) :679-688
[10]  
Foster R. H., 1998, DRUGS, V55, P737